Musely turns to alternative financing instead of a traditional venture round
Musely, a direct-to-consumer telemedicine company focused on compounded treatments for skin, hair, and menopause care, has secured more than $360 million in non-dilutive capital from General Catalyst’s Customer Value Fund, according to TechCrunch. The deal stands out in a startup market still dominated by either equity fundraising or conventional debt, because Musely says this structure gives it access to major growth capital without giving up ownership or taking on a standard interest-bearing loan.
The company’s chief executive and co-founder, Jack Jia, told TechCrunch he had not been actively seeking outside financing. Musely, founded in 2014 as a wellness community before pivoting in 2019 to prescription skincare, had already been cash-flow positive for years, he said. That financial position appears to have given the company leverage to reject more conventional venture offers that would have diluted founder ownership.
Instead, Musely chose a structure tied to General Catalyst’s Customer Value Fund, or CVF, which is designed for companies with predictable revenue streams. Rather than taking equity, the fund provides growth capital that is repaid through a fixed, capped share of revenue generated from the funded growth efforts. Jia described the arrangement as mathematically more compelling than a bank loan and less expensive than a dilutive fundraising round.
Why the structure matters
The financing reflects a broader shift in how some later-stage growth companies are approaching expansion. For venture-backed startups, the standard playbook has long centered on raising increasingly large equity rounds to fund customer acquisition, market expansion, and hiring. But that path can be expensive for founders and early investors when valuations are under pressure or when the business already generates meaningful cash flow.
Musely’s case highlights an alternative model better suited to businesses that already know how to acquire customers and monetize them. If revenue is stable enough to forecast, non-dilutive growth funding can become a way to scale without resetting the cap table. That is especially relevant in direct-to-consumer health businesses, where customer acquisition costs can be high and sustained marketing investment is often necessary to maintain growth.
Jia framed the problem in practical terms: once a company reaches significant scale, it can require enormous new capital simply to keep climbing. For brands built around digital customer acquisition, profitable growth is often constrained less by product demand than by the cost of attracting additional customers at scale.
Growth capital aimed at customer acquisition
According to TechCrunch, Musely has served more than 1.2 million patients and has been growing revenue by an average of 50% year over year. The new capital is expected to support sales, marketing, and other customer acquisition efforts. That focus is significant because it suggests the company is using the financing not as a rescue measure, but as a lever to accelerate an operating model that is already working.
In other words, this is not a turnaround story. It is a bet that a business with proven demand can grow faster if it can spend more aggressively to reach and convert new customers, while still keeping financing costs within predictable bounds.
The approach also reveals how some investors are broadening the tools they use to back companies. Instead of relying solely on ownership stakes that pay off at exit, funds like CVF appear to be positioning themselves as growth enablers for businesses that may not need traditional venture capital at all. That could be appealing in sectors where disciplined operators want scale capital but want to avoid both dilution and the rigidity of bank underwriting.
What it signals for digital health and consumer startups
Musely’s financing may resonate beyond telemedicine. Consumer health companies sit at the intersection of healthcare delivery, software, subscription economics, and performance marketing. That mix creates a very specific funding challenge: companies can show real revenue and repeat purchasing, yet still need heavy upfront spending to acquire and retain customers.
If alternative structures like revenue-linked capital continue to gain traction, they could create a middle path between bootstrapping and venture dependence. For founders, the attraction is straightforward: preserve ownership, keep operational control, and fund expansion from the economics of the business itself. For investors, the appeal is exposure to growth without waiting for a liquidity event.
There are still limits to the model. It works best when revenue is predictable and customer acquisition can be measured closely enough to support repayment assumptions. It is less suited to speculative businesses, long research cycles, or companies still searching for product-market fit. But for companies that already have those fundamentals in place, the Musely deal suggests that capital markets for startups are becoming more flexible.
At a time when private funding remains more selective, Musely’s agreement with General Catalyst is notable not only for its size, but for what it says about the maturity of the business receiving it. The company did not need emergency funding or a visibility-boosting equity round. It needed a large pool of growth capital aligned with a cash-generating model. That distinction may become increasingly important as more startups age into profitability while still chasing expansion.
This article is based on reporting by TechCrunch. Read the original article.
Originally published on techcrunch.com
